Crossmark

Evaluating the relationship between antidrug antibodies and efficacy and safety outcomes in patients with Fabry disease receiving enzyme replacement therapy: a systematic literature review

Crossref DOI link: https://doi.org/10.1186/s13023-026-04438-8

Published Online: 2026-07-16

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Aguiar, Patricio

Bernat, John A.

Hughes, Derralynn https://orcid.org/0000-0003-4531-9173
License Information

Text and Data Mining valid from 2026-07-16

Version of Record valid from 2026-08-24
More Information

Article History

Received: 21 January 2026

Accepted: 31 May 2026

First Online: 16 July 2026

Declarations

Ethics approval and consent to participate: Not applicable.

Consent for publication: Not applicable.

Competing interests: JAB receives research support from Avrobio, BioMarin Pharmaceutical, Chiesi Farmaceutici, Denali Therapeutics, Idorsia Pharmaceuticals, Pfizer, Protalix BioTherapeutics, Sangamo Therapeutics, Sanofi, Takeda, and Travere Therapeutics, and has participated in advisory boards for Chiesi and Mirum Pharmaceuticals. PA receives grant/research support from Takeda, and speaker/travel honoraria from Alexion, Amicus Therapeutics, BioMarin, Chiesi, Sanofi-Genzyme, Takeda, and Ultragenyx. DH has received honoraria for speaking and consulting fees for advisory boards from AceLinkAcelink, Amicus, Chiesi, Freeline, Uniqure, Sangamo, Sanofi, and Takeda, administered through University College London consultants, and used in part to support research in lysosomal storage diseases.

Document is current

Any future updates will be listed below